AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7800156 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased blood glucose levels
Number of subjects: 0
Study 7800156 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 3396472 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime plus metronidazole
Number of subjects: 175
Study 3396472 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin
Number of subjects: 175
Study 29800584 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound unconditioned stimulus (UCS) - electric shock combined with a scream noise
Number of subjects: 274
Study 29800584 — intervention group
Group type: COMPARATOR
Intervention: Demographic factors (race, age, education, gender)
Number of subjects: 274
Study 28472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Demonstration-based training group
Number of subjects: 90
Study 28472588 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure group
Number of subjects: 90
Study 28472588 — intervention group
Group type: COMPARATOR
Intervention: Routine care-receiving group
Number of subjects: 90
Study 26258311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved packed red blood cells (CPRBCs)
Number of subjects: 256
Study 26258311 — intervention group
Group type: COMPARATOR
Intervention: Young liquid packed red blood cells (LPRBCs)
Number of subjects: 256
Study 26258311 — intervention group
Group type: COMPARATOR
Intervention: Old liquid packed red blood cells (LPRBCs)
Number of subjects: 256
Study 24119160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediopatellar plica (type A, B, or C)
Number of subjects: 342
Study 24119160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediopatellar plica
Number of subjects: 342
Study 21059991 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 36
Study 21059991 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 36
Study 21059991 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 18246678 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehmannia Oral Liquid
Number of subjects: 60
Study 18246678 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (Control)
Number of subjects: 60
Study 15170087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary radiation therapy (IRT) using rhenium-188-filled balloon system
Number of subjects: 187
Study 15170087 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 187
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/leucovorin
Number of subjects: 0
Study 11219972 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (bolus)
Number of subjects: 0
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate followed by i.v. bolus 5-FU
Number of subjects: 0
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-FU
Number of subjects: 0
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate/5-FU
Number of subjects: 0
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional 5-FU
Number of subjects: 0
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucovorin-modulated 5-FU
Number of subjects: 0
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted infusional 5-FU
Number of subjects: 0
Study 11219972 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 5-FU
Number of subjects: 0
Study 9640152 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1
Number of subjects: 40
Study 9640152 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1 with glycopyrrolate 200 micrograms
Number of subjects: 40
Study 9640152 — intervention group
Group type: COMPARATOR
Intervention: saline placebo only
Number of subjects: 40
Study 9640152 — intervention group
Group type: COMPARATOR
Intervention: glycopyrrolate 200 micrograms only
Number of subjects: 40
Study 9640152 — intervention group
Group type: EXPERIMENTAL
Intervention: glycopyrrolate 200 micrograms and remifentanil 1 microgram kg‐1 bolus over 30 s, followed by an infusion of 0.5 microgram kg‐1 min‐1
Number of subjects: 40
Study 8023668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol
Number of subjects: 20
Study 8023668 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study 2645918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg/d given in divided dosage) for twelve weeks
Number of subjects: 26
Study 2645918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 120 mg/d given in divided dosage) for four weeks
Number of subjects: 26
Study 1236737 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid mixture simulating casein
Number of subjects: 0
Study 1236737 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptic hydrolysate of casein
Number of subjects: 0
Study 1236737 — intervention group
Group type: COMPARATOR
Intervention: Control (fasting subjects)
Number of subjects: 0
Study 31688091 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisense-oligonucleotide therapy
Number of subjects: 0
Study 31688091 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA interference therapy
Number of subjects: 0
Study 30316998 — intervention group
Group type: EXPERIMENTAL
Intervention: PeerFIT (group lifestyle intervention enhanced with mobile health technology)
Number of subjects: 144
Study 30316998 — intervention group
Group type: COMPARATOR
Intervention: BEAT (one‐on‐one mobile lifestyle coaching with Basic Education in fitness and nutrition supported by a wearable Activity Tracking device)
Number of subjects: 144
Study 30316998 — intervention group
Group type: EXPERIMENTAL
Intervention: PeerFIT
Number of subjects: 144
Study 28805299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily
Number of subjects: 24
Study 28805299 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 5 mg twice daily
Number of subjects: 24
Study 25868579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Dexamethasone/Cisplatin (GDP)
Number of subjects: 519
Study 25868579 — intervention group
Group type: COMPARATOR
Intervention: Cytarabine/Dexamethasone/Cisplatin (DHAP)
Number of subjects: 519
Study 23020631 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning of teeth and dentures with individual instruction and re-instruction by a dentist (n = 27)
Number of subjects: 106
Study 23020631 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning of teeth and dentures with individual instruction and help from staff educated in dental hygiene (n = 26)
Number of subjects: 106
Study 23020631 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional cleaning of teeth and dentures with individual instruction without further remotivation (n = 26)
Number of subjects: 106
Study 23020631 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, n = 23)
Number of subjects: 106
Study 21398375 — intervention group
Group type: EXPERIMENTAL
Intervention: Core dissemination (provision of the 2000 Public Health System Clinical Practice Guideline and a tested smoking cessation program, including program supplies and training)
Number of subjects: 12
Study 21398375 — intervention group
Group type: EXPERIMENTAL
Intervention: Core dissemination and access to telephone counseling
Number of subjects: 12
Study 21398375 — intervention group
Group type: EXPERIMENTAL
Intervention: Core dissemination, telephone counseling access and outreach visits to clinics
Number of subjects: 12
Study 21398375 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 12
Study 18512816 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bovine type I collagen (500 microg/day)
Number of subjects: 168
Study 18512816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 16551144 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal cognitive-behavioral approach
Number of subjects: 0
Study 16551144 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated cognitive-behavioral approach
Number of subjects: 0
Study 16551144 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined universal plus indicated cognitive-behavioral approach
Number of subjects: 0
Study 16551144 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 16551144 — intervention group
Group type: COMPARATOR
Intervention: Universal intervention
Number of subjects: 0
Study 15070917 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol-drospirenone (OC)
Number of subjects: 54
Study 15070917 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (62.5 mg/d) plus Metformin (850 mg/d)
Number of subjects: 54
Study 15070917 — intervention group
Group type: COMPARATOR
Intervention: Ethinylestradiol-drospirenone (OC) alone
Number of subjects: 54
Study 15070917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol-drospirenone (OC) plus Flutamide-Metformin
Number of subjects: 54
Study 11458414 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCR
Number of subjects: 502
Study 11458414 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 502
Study 10137725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified control
Number of subjects: 1441
Study 10137725 — intervention group
Group type: COMPARATOR
Intervention: Conventional control
Number of subjects: 1441
Study 2577220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 20
Study 2577220 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg
Number of subjects: 20
Study 2577220 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 10 mg
Number of subjects: 20
Study 2577220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1098867 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (Septrin)
Number of subjects: 22
Study 1098867 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 22
Study 31295757 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician introducing counselor and psychology services (PI)
Number of subjects: 100
Study 31295757 — intervention group
Group type: COMPARATOR
Intervention: Counselor introducing psychology services alone (CI)
Number of subjects: 100
Study 31295757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PI and CI)
Number of subjects: 100
Study 31295757 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician offering psychology services
Number of subjects: 100
Study 31295757 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived helpfulness of psychology services for self
Number of subjects: 100
Study 31295757 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived helpfulness of psychology services for family/caregivers
Number of subjects: 100
Study 31295757 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger patients (<40 years) preference
Number of subjects: 100
Study 27644454 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS combined with virtual reality training
Number of subjects: 20
Study 27644454 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation combined with virtual reality training
Number of subjects: 20
Study 26087226 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based alcohol treatment program with intensive asynchronous therapeutic support
Number of subjects: 144
Study 23525086 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing for closed fractures
Number of subjects: 1226
Study 23525086 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing for closed fractures (first 35 patients)
Number of subjects: 1226
Study 23525086 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing for closed fractures (after 543 patients)
Number of subjects: 1226
Study 23525086 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed nailing for open fractures (after 62 patients)
Number of subjects: 1226
Study 21266647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean sensor glucose concentration (area under the curve)
Number of subjects: 252
Study 21266647 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean sensor glucose concentrations
Number of subjects: 252
Study 21266647 — intervention group
Group type: EXPERIMENTAL
Intervention: Root mean square of the errors
Number of subjects: 252
Study 21266647 — intervention group
Group type: EXPERIMENTAL
Intervention: Median absolute difference
Number of subjects: 252
Study 19182079 — intervention group
Group type: EXPERIMENTAL
Intervention: Bobath Concept
Number of subjects: 813
Study 19182079 — intervention group
Group type: COMPARATOR
Intervention: Other approaches
Number of subjects: 813
Study 16885220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to restore normal blood flow
Number of subjects: 87
Study 16885220 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 87
Study 15283001 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (200 mg) plus carbidopa (50 mg) administered at night (11 pm)
Number of subjects: 24
Study 15283001 — intervention group
Group type: COMPARATOR
Intervention: L-dopa (200 mg) plus carbidopa (50 mg) administered during the day (11 am)
Number of subjects: 24
Study 11738102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 80
Study 11738102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8989345 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg/kg RSV‐IGIV
Number of subjects: 510
Study 8989345 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1% albumin)
Number of subjects: 510
Study 8235924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 500 mg intramuscularly
Number of subjects: 613
Study 8235924 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 250 mg intramuscularly
Number of subjects: 613
Study 3321412 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 200 mg or 400 mg b.i.d. for 7 days
Number of subjects: 651
Study 3321412 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg b.i.d.
Number of subjects: 651
Study 3321412 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 651
Study 3321412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin, cephalothin, sulfamethoxazole
Number of subjects: 651
Study 3321412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid, mecillinam
Number of subjects: 651
Study 3321412 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime, gentamicin, trimethoprim
Number of subjects: 651
Study 31122227 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Group (n=37)
Number of subjects: 74
Study 31122227 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Group (n=37)
Number of subjects: 74
Study 29912453 — intervention group
Group type: EXPERIMENTAL
Intervention: rMVA-H5
Number of subjects: 79
Study 29912453 — intervention group
Group type: COMPARATOR
Intervention: Vector control
Number of subjects: 79
Study 26783237 — intervention group
Group type: EXPERIMENTAL
Intervention: Early fibrinolysis
Number of subjects: 1859
Study 26783237 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 1859
Study 26783237 — intervention group
Group type: COMPARATOR
Intervention: Both reperfusion strategies
Number of subjects: 1859
Study 23632272 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS)
Number of subjects: 100
Study 22101497 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) at baseline, month 1, and month 2
Number of subjects: 18
Study 22101497 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IVB and macular grid laser photocoagulation
Number of subjects: 18
Study 19640941 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive booklet on respiratory tract infections
Number of subjects: 528
Study 19640941 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 528
Study 17311647 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 50 mu 12 h subcutaneously for a 1-2 yr period
Number of subjects: 32
Study 17311647 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet/day)
Number of subjects: 32
Study 17311647 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 32
Study 17311647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16235871 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Matrix (MM) model of supervision
Number of subjects: 0
Study 16235871 — intervention group
Group type: EXPERIMENTAL
Intervention: Centre for Health and Social Studies (CHESS) model
Number of subjects: 0
Study 16235871 — intervention group
Group type: COMPARATOR
Intervention: Control (District C)
Number of subjects: 0
Study 11918228 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml of cod liver oil with vitamin D (n = 575)
Number of subjects: 1144
Study 11918228 — intervention group
Group type: COMPARATOR
Intervention: 5 ml of cod liver oil without vitamin D (n = 569)
Number of subjects: 1144
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: American Cancer Society (ACS) guidelines
Number of subjects: 300
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: US Preventive Services Task Force (USPSTF) guidelines
Number of subjects: 300
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: Compilation of various guidelines
Number of subjects: 300
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: No guidelines
Number of subjects: 300
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer screening practices
Number of subjects: 300
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease screening practices
Number of subjects: 300
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of depression
Number of subjects: 300
Study 9439181 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity/diabetes mellitus treatment
Number of subjects: 300
Study 8129410 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin (0.025% cream)
Number of subjects: 22
Study 8129410 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral isotretinoin (10 mg/d)
Number of subjects: 22
Study 8129410 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined use of isotretinoin and tretinoin
Number of subjects: 22
Study 8129410 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin cream
Number of subjects: 22
Study 8129410 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 22
Study 2679513 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 vaginal gel (1 or 2mg, repeated if necessary at 6 hours)
Number of subjects: 320
Study 2679513 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin (via amniotomy)
Number of subjects: 320
Study 1097747 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 0
Study 1097747 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0
Study 30716123 — intervention group
Group type: EXPERIMENTAL
Intervention: Copenhagen Triage Algorithm (CTA)
Number of subjects: 45347
Study 30716123 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Process Triage (ADAPT)
Number of subjects: 45347
Study 27863326 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game intervention (AVG), 30-35 minutes/day for 16 weeks
Number of subjects: 21
Study 27863326 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game intervention (AVG)
Number of subjects: 21
Study 25700289 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 24‐hour Holter ECG monitoring with AF auto‐detect external loop recorder for 30 days.
Number of subjects: 237
Study 25700289 — intervention group
Group type: COMPARATOR
Intervention: APB count categories based on Holter ECG monitoring.
Number of subjects: 237
Study 22672611 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic bone graft Straumann Bone Ceramic (SBC) with collagen barrier
Number of subjects: 27
Study 22672611 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral (DBBM) with collagen barrier
Number of subjects: 27
Study 21123762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of atrial natriuretic peptide (ANP) at 10 ng·kg(‐1)·min(‐1)
Number of subjects: 0
Study 21123762 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of angiotensin II (ANG II) at 10 ng·kg(‐1)·min(‐1)
Number of subjects: 0
Study 21123762 — intervention group
Group type: EXPERIMENTAL
Intervention: ANG II with simultaneous infusion of nitroprusside
Number of subjects: 0
Study 21123762 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intravenous infusion of ANP (10 ng·kg(‐1)·min(‐1)) with ANG II and nitroprusside
Number of subjects: 0
Study 19204058 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal corticosteroids (dexamethasone), total dose tertiles: <0.9, 0.9‐1.9, and >/=1.9 mg/kg
Number of subjects: 2358
Study 19204058 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal corticosteroids (dexamethasone) after 33 weeks' postmenstrual age
Number of subjects: 2358
Study 19204058 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal corticosteroids (dexamethasone) in neonates at high risk for bronchopulmonary dysplasia
Number of subjects: 2358
Study 17292022 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (RCT)
Number of subjects: 145
Study 17292022 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (OS)
Number of subjects: 145
Study 15365275 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril up-titration (40 mg for 8 weeks)
Number of subjects: 1096
Study 15365275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril plus candesartan (16 mg for 2 weeks followed by 32 mg for 6 weeks)
Number of subjects: 1096
Study 15365275 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc pooled analysis of lisinopril plus candesartan
Number of subjects: 1096
Study 16232173 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (n=43)
Number of subjects: 120